July 2017: We have reviewed the evidence and made new recommendations on treating Parkinson's disease symptoms, deep brain stimulation, monitoring and managing impulse control disorders, and palliative care. These recommendations are marked .
We have also made some changes without an evidence review:
changes made to clarify the action of a recommendation
the timeframe for referral was removed because it was not evidence based.
These recommendations are marked [2006, amended 2017].
Minor changes since publication
December 2020: We added advice for women who are pregnant or who are planning a pregnancy to recommendations 1.5.2 and 1.5.3, in line with the MHRA safety advice on modafinil.
September 2020: We linked to the NICE guideline on supporting adult carers in recommendation 1.1.4 and incorporated footnotes into the recommendations in line with accessibility requirements.
October 2019: A footnote was added to reflect a change in marketing authorisation status for botulinum neurotoxin type A preparations.